Therapeutic Effect of Yttrium Oxide Nanoparticles for the Treatment of Fulminant Hepatic Failure

Abstract

Aim: To explore the potential therapeutic effect of yttrium oxide nanoparticles (Y₂O₃ NPs) on fulminant hepatic failure. Materials & methods: RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of Y₂O₃ NPs. Results: Y₂O₃ NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation in vitro. A single intraperitoneal administration of Y₂O₃ NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. Y₂O₃ NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. Conclusion: Y₂O₃ NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.

Keywords:

• cerium oxide nanoparticles
• D-galactosamine
• fulminant hepatic failure
• inflammation
• lipopolysaccharide
• NF-κB activation
• reactive oxygen species
• yttrium oxide nanoparticles

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:www.tandfonline.com/doi/full/10.2217/epi-2016-0184

Author contributions

X Song, P Shang and Z Sun carried out the studies and drafted the manuscript; M Lu performed the animal experiment; G You made substantial modifications to the manuscript; S Yan contributed to the study statistical analyses; G Chen and H Zhou are the principal investigators and take responsibility for all conceptual and technical aspects of this study. All authors have read and approved the manuscript for publication.

Financial & competing interests disclosure

This work has been supported by grants from the National Natural Science Foundation of China (grant numbers 81600148 and 81700181). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was in conformity with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the Academy of Military Medical Sciences. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.